White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.

202
19
Favorite

White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.

Barron's2021-09-09

The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal. The plan will allow Medicare to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

202

Report

Comment（19）

Bull1973
·2021-09-10
Yes
Reply
3
Report
Fold Replies
- Ryacleigh:
  ??
  2021-09-14
  Reply
  Report
KH321
·2021-09-10
OK
Reply
4
Report
Fold Replies
- Bull1973:
  Yes
  2021-09-10
  Reply
  Report
LST3
·2021-09-10
Good
Reply
3
Report
SPOT_ON
·2021-09-10
Like n follow
Reply
7
Report
Fold Replies
- SPOT_ON:
  ?
  2021-09-10
  Reply
  Report
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-09-10
  Reply
  Report
blackblack1
·2021-09-10
Pls like
Reply
6
Report
Fold Replies
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-09-10
  Reply
  Report
- joyciology:
  done
  2021-09-10
  Reply
  Report
- DMC8:
  Okay ✅
  2021-09-10
  Reply
  Report
Rdhillydally
·2021-09-10
.
Reply
7
Report
HENRYCSC
·2021-09-09
Good
Reply
2
Report
CIG
·2021-09-09
Need fine tuning, can't fix without delicate rulings.
Reply
3
Report
GeraldHere
·2021-09-09
Hi
Reply
4
Report
Alfred1007
·2021-09-09
This put pharma companies in dilemma, if you spend billions but your drug can't bring much profit, the risk vs reward doesn't pay off...it is a good intention, but need to strike a balance.
Reply
6
Report
Fold Replies
- joshc:
  yes, and if there is such price negotiation (manipulation??) then isn't it harder for pharma coys to determine what is their revenue going to be when they are first developing the drug?
  2021-09-10
  Reply
  Report
- LohYK:
  that why the price flux are so extreme
  2021-09-09
  Reply
  Report
chaicka
·2021-09-09
Yet on the flip side, there are decades old drugs which are getting ridiculously expensive. E.g. Panadol is now so expensive when it is not a new drug at all. Maybe the policy needs some kind of tweaking such as ‘applicable to drugs which have been release for >5 years, including any minor revisions to the same drug’.
Reply
5
Report
Fold Replies
- koolgal:
  Yes Panadol is very expensive in Singapore. ?
  2021-09-23
  Reply
  Report
- ALearner:
  Panadol is a generic drug, the poliCy wikl imPact proprietary drug the most i guess
  2021-09-10
  Reply
  Report
- chaicka:
  I know cause i worked in Pharma firm before. What i meant is old drugs that have been around for 20-40 years have already recoup R&D costs yet retail price keep increase is not right.
  2021-09-09
  Reply
  Report
View more 2 comments
AxelOng
·2021-09-09
If u control the price there will be not motivation to spend money in r n d. No good for research
Reply
5
Report
Fold Replies
- JamesArthur:
  Agree to the max
  2021-09-09
  Reply
  Report
Wheee
·2021-09-09
Like
Reply
6
Report
Fold Replies
- JeremyKok:
  hi. please like and comment back. thank you.
  2021-09-10
  Reply
  Report
- D199991D:
  Done
  2021-09-09
  Reply
  Report
SiewWeng
·2021-09-09
Yay
Reply
5
Report
Ygh
·2021-09-09
Hi
Reply
6
Report
Fold Replies
- SiewWeng:
  Hey
  2021-09-09
  Reply
  Report
firstfruits
·2021-09-09
generic and biosimilar should be advantaged by this policy
Reply
5
Report
Fold Replies
- joshc:
  generics and biosimilar makers FTW
  2021-09-10
  Reply
  Report
Gladys12345
·2021-09-09
Please like
Reply
8
Report
Fold Replies
- Gyawh:
  ok
  2021-09-09
  Reply
  Report
- St1143:
  Done
  2021-09-09
  Reply
  Report
- HueiKwang:
  Liked
  2021-09-09
  Reply
  Report
View more 1 comments
Bll
·2021-09-09
Like pls
Reply
10
Report
Fold Replies
- Ygh:
  Done
  2021-09-09
  Reply
  Report
- Gladys12345:
  Please like
  2021-09-09
  Reply
  Report
Degenerated
·2021-09-09
Drop more. I want to buu pfizer
Reply
7
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1176976417?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-09 22:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176976417","market":"us","top_or_hot":-1,"title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","media":"Barron's","content":"<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Source Link</a>\n\n</div>\n","source":"lsy1610680873436","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","article_id":"1176976417","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","pubTimestamp":1631197026,"sourceInfo":{"source_id":"lsy1610680873436","name":"Barron's"},"weMediaInfo":null,"summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","collect":0,"end_time":0,"defaultTopTitle":"marketwatch.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生","LLY":"礼来","PFE":"辉瑞"},"translate_title":"《华尔街日报》称，白宫将宣布药品定价计划。制药股下跌。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9,"LLY":0.9,"PFE":0.9},"content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":883147957,"gmtCreate":1631230140879,"gmtModify":1676530500381,"author":{"id":"3584680402793671","authorId":"3584680402793671","name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3584680402793671","authorIdStr":"3584680402793671"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883147957","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5867978,"gmtCreate":1631633075577,"gmtModify":1663233877965,"authorId":3566723689439669,"author":{"id":3566723689439669,"idStr":"3566723689439669","authorId":3566723689439669,"name":"Ryacleigh","avatar":"https://static.tigerbbs.com/99db9b9b2d5d303db43970c31a6ba528","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883147957,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"},{"id":883132949,"gmtCreate":1631224493981,"gmtModify":1676530498641,"author":{"id":"3586451610703869","authorId":"3586451610703869","name":"KH321","avatar":"https://static.tigerbbs.com/c1bb8bd7d6d5df5f9732871fe60999ea","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586451610703869","authorIdStr":"3586451610703869"},"htmlText":"OK&nbsp;","listText":"OK&nbsp;","text":"OK","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883132949","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5811122,"gmtCreate":1631230149003,"gmtModify":1663233636148,"authorId":3584680402793671,"author":{"id":3584680402793671,"idStr":"3584680402793671","authorId":3584680402793671,"name":"Bull1973","avatar":"https://static.tigerbbs.com/866d29bf88ff7363d121a5ccc6028aae","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883132949,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":883197549,"gmtCreate":1631223252281,"gmtModify":1676530498511,"author":{"id":"3576578158811365","authorId":"3576578158811365","name":"LST3","avatar":"https://static.tigerbbs.com/5ebefe56c7d81742050e1a8d5a94ef9a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576578158811365","authorIdStr":"3576578158811365"},"htmlText":"Good&nbsp;","listText":"Good&nbsp;","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883197549","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883194676,"gmtCreate":1631222986895,"gmtModify":1676530498495,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":1,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Like n follow","listText":"Like n follow","text":"Like n follow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883194676","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5811041,"gmtCreate":1631229886728,"gmtModify":1663233638338,"authorId":3582922989777578,"author":{"id":3582922989777578,"idStr":"3582922989777578","authorId":3582922989777578,"name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.27%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883194676,"type":1,"supId":5810854,"prevId":0,"content":"?","text":"?","html":"?"},{"id":5810854,"gmtCreate":1631229064386,"gmtModify":1663233638036,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883194676,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"EN"},{"id":883191131,"gmtCreate":1631221947123,"gmtModify":1676530498372,"author":{"id":"4087735305621010","authorId":"4087735305621010","name":"blackblack1","avatar":"https://static.tigerbbs.com/77a3f9b815b90862b1826692953a69dd","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4087735305621010","authorIdStr":"4087735305621010"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/883191131","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5810857,"gmtCreate":1631229086641,"gmtModify":1663233636033,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883191131,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":5810268,"gmtCreate":1631225152948,"gmtModify":1663233633640,"authorId":3582108671334900,"author":{"id":3582108671334900,"idStr":"3582108671334900","authorId":3582108671334900,"name":"joyciology","avatar":"https://static.tigerbbs.com/bd90c4b20dfdf9210ef5daec9af84af3","vip":1,"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883191131,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"},{"id":5810050,"gmtCreate":1631222417400,"gmtModify":1663233633627,"authorId":3579992296424941,"author":{"id":3579992296424941,"idStr":"3579992296424941","authorId":3579992296424941,"name":"DMC8","avatar":"https://static.tigerbbs.com/65aa8f5f6299558ce2ab36482793f750","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883191131,"type":1,"supId":0,"prevId":0,"content":"Okay ✅","text":"Okay ✅","html":"Okay ✅"}],"langContent":"EN"},{"id":883190528,"gmtCreate":1631220204964,"gmtModify":1676530498174,"author":{"id":"3576861864918846","authorId":"3576861864918846","name":"Rdhillydally","avatar":"https://community-static.tradeup.com/news/6692062d2c0dfb80aa2a783ea4d62584","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3576861864918846","authorIdStr":"3576861864918846"},"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883190528","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883310561,"gmtCreate":1631201107353,"gmtModify":1676530496068,"author":{"id":"3575091428590185","authorId":"3575091428590185","name":"HENRYCSC","avatar":"https://static.tigerbbs.com/6d47a6dec25b21dc547a5b982674c499","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575091428590185","authorIdStr":"3575091428590185"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883310561","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883338810,"gmtCreate":1631200693830,"gmtModify":1676530495855,"author":{"id":"3583974841960176","authorId":"3583974841960176","name":"CIG","avatar":"https://static.tigerbbs.com/6c2077e2370e1ffcaca7e29b875be2be","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"idStr":"3583974841960176","authorIdStr":"3583974841960176"},"htmlText":"Need fine tuning, can't fix without delicate rulings.","listText":"Need fine tuning, can't fix without delicate rulings.","text":"Need fine tuning, can't fix without delicate rulings.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883338810","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883399484,"gmtCreate":1631199792848,"gmtModify":1676530495604,"author":{"id":"3557488303457204","authorId":"3557488303457204","name":"GeraldHere","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3557488303457204","authorIdStr":"3557488303457204"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883399484","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883309204,"gmtCreate":1631199173008,"gmtModify":1676530495373,"author":{"id":"3570656625926041","authorId":"3570656625926041","name":"Alfred1007","avatar":"https://static.tigerbbs.com/81d8406380cbc0525927f00a9510f2fa","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3570656625926041","authorIdStr":"3570656625926041"},"htmlText":"This put pharma companies in dilemma, if you spend billions but your drug can't bring much profit, the risk vs reward doesn't pay off...it is a good intention, but need to strike a balance.","listText":"This put pharma companies in dilemma, if you spend billions but your drug can't bring much profit, the risk vs reward doesn't pay off...it is a good intention, but need to strike a balance.","text":"This put pharma companies in dilemma, if you spend billions but your drug can't bring much profit, the risk vs reward doesn't pay off...it is a good intention, but need to strike a balance.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883309204","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5812843,"gmtCreate":1631235947463,"gmtModify":1663233643347,"authorId":3570623270313531,"author":{"id":3570623270313531,"idStr":"3570623270313531","authorId":3570623270313531,"name":"joshc","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883309204,"type":1,"supId":0,"prevId":0,"content":"yes, and if there is such price negotiation (manipulation??) then isn't it harder for pharma coys to determine what is their revenue going to be when they are first developing the drug?","text":"yes, and if there is such price negotiation (manipulation??) then isn't it harder for pharma coys to determine what is their revenue going to be when they are first developing the drug?","html":"yes, and if there is such price negotiation (manipulation??) then isn't it harder for pharma coys to determine what is their revenue going to be when they are first developing the drug?"},{"id":5808558,"gmtCreate":1631199456773,"gmtModify":1663233624638,"authorId":3568070265339857,"author":{"id":3568070265339857,"idStr":"3568070265339857","authorId":3568070265339857,"name":"LohYK","avatar":"https://static.tigerbbs.com/d6add0343094f5e965e831fa432314ef","vip":1,"crmLevel":8,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883309204,"type":1,"supId":0,"prevId":0,"content":"that why the price flux are so <u>extreme</u>","text":"that why the price flux are so <u>extreme</u>","html":"that why the price flux are so <u>extreme</u>"}],"langContent":"EN"},{"id":883947999,"gmtCreate":1631198458211,"gmtModify":1676530495017,"author":{"id":"4090019857770890","authorId":"4090019857770890","name":"chaicka","avatar":"https://static.tigerbbs.com/c0c291a2a7983f128cf68e5b01fedd73","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4090019857770890","authorIdStr":"4090019857770890"},"htmlText":"Yet on the flip side, there are decades old drugs which are getting ridiculously expensive. E.g. Panadol is now so expensive when it is not a new drug at all. Maybe the policy needs some kind of tweaking such as ‘applicable to drugs which have been release for &gt;5 years, including any minor revisions to the same drug’.","listText":"Yet on the flip side, there are decades old drugs which are getting ridiculously expensive. E.g. Panadol is now so expensive when it is not a new drug at all. Maybe the policy needs some kind of tweaking such as ‘applicable to drugs which have been release for &gt;5 years, including any minor revisions to the same drug’.","text":"Yet on the flip side, there are decades old drugs which are getting ridiculously expensive. E.g. Panadol is now so expensive when it is not a new drug at all. Maybe the policy needs some kind of tweaking such as ‘applicable to drugs which have been release for >5 years, including any minor revisions to the same drug’.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":5,"repostSize":0,"link":"https://ttm.financial/post/883947999","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5967590,"gmtCreate":1632367417651,"gmtModify":1663234313731,"authorId":3559581955535845,"author":{"id":3559581955535845,"idStr":"3559581955535845","authorId":3559581955535845,"name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","vip":2,"currentWearingBadge":{"badgeId":"c4ee29b388ff41cc8462b3b7ea00d1e2-1","templateUuid":"c4ee29b388ff41cc8462b3b7ea00d1e2","name":"Monthly Top Contributor","description":"Top 3 Contributors with the most and best Editor's Picks every month","bigImgUrl":"https://static.tigerbbs.com/b0cad6192443c33dca826a001250fbd4","smallImgUrl":"https://static.tigerbbs.com/5ccd98c646815ce7610b0df338e060cc","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/TW/9000980585","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.02","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":2003},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.11.22","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":883947999,"type":1,"supId":0,"prevId":0,"content":"Yes Panadol is very expensive in Singapore. ?","text":"Yes Panadol is very expensive in Singapore. ?","html":"Yes Panadol is very expensive in Singapore. ?"},{"id":5818011,"gmtCreate":1631264826558,"gmtModify":1663233666450,"authorId":3581627611317712,"author":{"id":3581627611317712,"idStr":"3581627611317712","authorId":3581627611317712,"name":"ALearner","avatar":"https://static.tigerbbs.com/dd4e09038044887c08337f0d263b9446","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883947999,"type":1,"supId":0,"prevId":0,"content":"Panadol is a generic drug, the poliCy wikl imPact proprietary drug the most i guess ","text":"Panadol is a generic drug, the poliCy wikl imPact proprietary drug the most i guess ","html":"Panadol is a generic drug, the poliCy wikl imPact proprietary drug the most i guess "},{"id":5809027,"gmtCreate":1631201558166,"gmtModify":1663233627538,"authorId":4090019857770890,"author":{"id":4090019857770890,"idStr":"4090019857770890","authorId":4090019857770890,"name":"chaicka","avatar":"https://static.tigerbbs.com/c0c291a2a7983f128cf68e5b01fedd73","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.47%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883947999,"type":1,"supId":5808847,"prevId":0,"content":"I know cause i worked in Pharma firm before. What i meant is old drugs that have been around for 20-40 years have already recoup R&amp;D costs yet retail price keep increase is not right.","text":"I know cause i worked in Pharma firm before. What i meant is old drugs that have been around for 20-40 years have already recoup R&amp;D costs yet retail price keep increase is not right.","html":"I know cause i worked in Pharma firm before. What i meant is old drugs that have been around for 20-40 years have already recoup R&amp;D costs yet retail price keep increase is not right."},{"id":5808847,"gmtCreate":1631200753939,"gmtModify":1663233625841,"authorId":9000000000000155,"author":{"id":9000000000000155,"idStr":"9000000000000155","authorId":9000000000000155,"name":"来一口汤","avatar":"https://static.tigerbbs.com/9f649536eb646f48146c16b7080d53da","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883947999,"type":1,"supId":0,"prevId":0,"content":"研发就是最大的支出，之前想不通为什么一些靶向药那么贵，后来看了一些文章才知道研发的费用都是天文数字。","text":"研发就是最大的支出，之前想不通为什么一些靶向药那么贵，后来看了一些文章才知道研发的费用都是天文数字。","html":"研发就是最大的支出，之前想不通为什么一些靶向药那么贵，后来看了一些文章才知道研发的费用都是天文数字。"},{"id":5808556,"gmtCreate":1631199437580,"gmtModify":1663233623458,"authorId":3479274822738867,"author":{"id":3479274822738867,"idStr":"3479274822738867","authorId":3479274822738867,"name":"路人丙钉钉","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883947999,"type":1,"supId":0,"prevId":0,"content":"每一次修改对于药企而言都是伤筋动骨的，他们也必然会想尽办法规避这种风险，毕竟收回研发成本才是第一位的","text":"每一次修改对于药企而言都是伤筋动骨的，他们也必然会想尽办法规避这种风险，毕竟收回研发成本才是第一位的","html":"每一次修改对于药企而言都是伤筋动骨的，他们也必然会想尽办法规避这种风险，毕竟收回研发成本才是第一位的"}],"langContent":"EN"},{"id":883955816,"gmtCreate":1631197939835,"gmtModify":1676530494756,"author":{"id":"4089463306606890","authorId":"4089463306606890","name":"AxelOng","avatar":"https://static.tigerbbs.com/8eaa7b50259b0329b74e09bc501ecd38","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"4089463306606890","authorIdStr":"4089463306606890"},"htmlText":"If u control the price there will be not motivation to spend money in r n d. No good for research&nbsp;","listText":"If u control the price there will be not motivation to spend money in r n d. No good for research&nbsp;","text":"If u control the price there will be not motivation to spend money in r n d. No good for research","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883955816","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808210,"gmtCreate":1631198020753,"gmtModify":1663233626834,"authorId":3574122255023758,"author":{"id":3574122255023758,"idStr":"3574122255023758","authorId":3574122255023758,"name":"JamesArthur","avatar":"https://static.tigerbbs.com/0230d592c84aee6b78c6136a020bbb52","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883955816,"type":1,"supId":0,"prevId":0,"content":"Agree to the max","text":"Agree to the max","html":"Agree to the max"}],"langContent":"EN"},{"id":883925892,"gmtCreate":1631197562316,"gmtModify":1676530494424,"author":{"id":"3580123620847057","authorId":"3580123620847057","name":"Wheee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580123620847057","authorIdStr":"3580123620847057"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883925892","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5810882,"gmtCreate":1631229174040,"gmtModify":1663233635841,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883925892,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":5808270,"gmtCreate":1631198244296,"gmtModify":1663233623457,"authorId":3577352301253695,"author":{"id":3577352301253695,"idStr":"3577352301253695","authorId":3577352301253695,"name":"D199991D","avatar":"https://static.tigerbbs.com/49e24e0e3faeb8d389ad5d2db8a0e240","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883925892,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":883926285,"gmtCreate":1631197468247,"gmtModify":1676530494393,"author":{"id":"3585252654864862","authorId":"3585252654864862","name":"SiewWeng","avatar":"https://static.tigerbbs.com/53df5a10f848dd9d79558c4f7a3fb9f8","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3585252654864862","authorIdStr":"3585252654864862"},"htmlText":"Yay","listText":"Yay","text":"Yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883926285","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883928227,"gmtCreate":1631197407669,"gmtModify":1676530494362,"author":{"id":"3572529600057361","authorId":"3572529600057361","name":"Ygh","avatar":"https://static.tigerbbs.com/09f51a5273fd07aa4765ea2a333521d1","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3572529600057361","authorIdStr":"3572529600057361"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883928227","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808087,"gmtCreate":1631197474892,"gmtModify":1663233623336,"authorId":3585252654864862,"author":{"id":3585252654864862,"idStr":"3585252654864862","authorId":3585252654864862,"name":"SiewWeng","avatar":"https://static.tigerbbs.com/53df5a10f848dd9d79558c4f7a3fb9f8","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.28","exceedPercentage":"80.14%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883928227,"type":1,"supId":0,"prevId":0,"content":"Hey","text":"Hey","html":"Hey"}],"langContent":"EN"},{"id":883928961,"gmtCreate":1631197382853,"gmtModify":1676530494346,"author":{"id":"3562413816387860","authorId":"3562413816387860","name":"firstfruits","avatar":"https://static.tigerbbs.com/10628f9c1ecd1b1ed688fe5c74ad3511","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562413816387860","authorIdStr":"3562413816387860"},"htmlText":"generic and biosimilar should be advantaged by this policy","listText":"generic and biosimilar should be advantaged by this policy","text":"generic and biosimilar should be advantaged by this policy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883928961","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5812860,"gmtCreate":1631236021942,"gmtModify":1663233644240,"authorId":3570623270313531,"author":{"id":3570623270313531,"idStr":"3570623270313531","authorId":3570623270313531,"name":"joshc","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883928961,"type":1,"supId":0,"prevId":0,"content":"generics and biosimilar makers <u>FTW</u>","text":"generics and biosimilar makers <u>FTW</u>","html":"generics and biosimilar makers <u>FTW</u>"}],"langContent":"EN"},{"id":883923846,"gmtCreate":1631197287485,"gmtModify":1676530494314,"author":{"id":"3586416730091306","authorId":"3586416730091306","name":"Gladys12345","avatar":"https://static.tigerbbs.com/8c9e9a64e6e530eabc1c7af92859e0a7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3586416730091306","authorIdStr":"3586416730091306"},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/883923846","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808040,"gmtCreate":1631197303194,"gmtModify":1663233624541,"authorId":4087968261291200,"author":{"id":4087968261291200,"idStr":"4087968261291200","authorId":4087968261291200,"name":"Gyawh","avatar":"https://static.tigerbbs.com/b7e98e2fe85754b609a26fc86ffd7b82","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883923846,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":5808114,"gmtCreate":1631197571550,"gmtModify":1663233624343,"authorId":4090810527054110,"author":{"id":4090810527054110,"idStr":"4090810527054110","authorId":4090810527054110,"name":"St1143","avatar":"https://static.tigerbbs.com/c371329fac0ebdfc2f72b724292a0763","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883923846,"type":1,"supId":0,"prevId":0,"content":"<u>Done</u>","text":"<u>Done</u>","html":"<u>Done</u>"},{"id":5808059,"gmtCreate":1631197350457,"gmtModify":1663233624328,"authorId":3576803977335172,"author":{"id":3576803977335172,"idStr":"3576803977335172","authorId":3576803977335172,"name":"HueiKwang","avatar":"https://static.tigerbbs.com/0b383f4a30ca6333c52769097600ed0b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883923846,"type":1,"supId":0,"prevId":0,"content":"Liked","text":"Liked","html":"Liked"},{"id":5808117,"gmtCreate":1631197587141,"gmtModify":1663233621845,"authorId":3580123620847057,"author":{"id":3580123620847057,"idStr":"3580123620847057","authorId":3580123620847057,"name":"Wheee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883923846,"type":1,"supId":5808059,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":883920440,"gmtCreate":1631197182980,"gmtModify":1676530494277,"author":{"id":"3575152525326279","authorId":"3575152525326279","name":"Bll","avatar":"https://static.tigerbbs.com/b372fc92d67296f5ba36af78d1d6e935","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575152525326279","authorIdStr":"3575152525326279"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883920440","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5808078,"gmtCreate":1631197421435,"gmtModify":1663233624346,"authorId":3572529600057361,"author":{"id":3572529600057361,"idStr":"3572529600057361","authorId":3572529600057361,"name":"Ygh","avatar":"https://static.tigerbbs.com/09f51a5273fd07aa4765ea2a333521d1","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883920440,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":5808037,"gmtCreate":1631197294279,"gmtModify":1663233623456,"authorId":3586416730091306,"author":{"id":3586416730091306,"idStr":"3586416730091306","authorId":3586416730091306,"name":"Gladys12345","avatar":"https://static.tigerbbs.com/8c9e9a64e6e530eabc1c7af92859e0a7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883920440,"type":1,"supId":0,"prevId":0,"content":"Please like","text":"Please like","html":"Please like"}],"langContent":"EN"},{"id":883967690,"gmtCreate":1631197119810,"gmtModify":1676530494247,"author":{"id":"3582457483215828","authorId":"3582457483215828","name":"Degenerated","avatar":"https://static.tigerbbs.com/fcad9a3e2865b545e3a1f4ec2cc9917a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582457483215828","authorIdStr":"3582457483215828"},"htmlText":"Drop more. I want to buu pfizer","listText":"Drop more. I want to buu pfizer","text":"Drop more. I want to buu pfizer","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883967690","repostId":1176976417,"repostType":4,"repost":{"id":"1176976417","pubTimestamp":1631197026,"share":"https://ttm.financial/m/news/1176976417?lang=&edition=fundamental","pubTime":"2021-09-09 22:17","market":"us","language":"en","title":"White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down.","url":"https://stock-news.laohu8.com/highlight/detail?id=1176976417","media":"Barron's","summary":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according","content":"<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from <i>The Wall Street Journal</i>.</p>\n<p>The plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the <i>Journal</i> report.</p>\n<p>The plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.</p>\n<p>The S&amp;P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&amp;P 500,&nbsp;which has risen 20.2%. The SPDR S&amp;P Biotech</p>\n<p>exchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.</p>\n<p>Shares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson &amp; Johnson&nbsp;(JNJ) shares declined 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/1f3b476333002ca1b549be932aa2a442\" tg-width=\"275\" tg-height=\"163\" width=\"100%\" height=\"auto\"></p>\n<p>Worries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.</p>\n<p>According to the <i>Journal</i>, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.</p>\n<p>“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”</p>\n<p>Lilly CEO David Ricks also spoke on the call.</p>\n<p>“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.</p>\n<p>In addition to the drug-pricing plan, the <i>New York Times</i> reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.</p>","source":"lsy1610680873436","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>White House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhite House Will Announce Drug-Pricing Plan, WSJ Says. Pharma Stocks Are Down. \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 22:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews><strong>Barron's</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","LLY":"礼来"},"source_url":"https://www.marketwatch.com/articles/white-house-drug-pricing-pharma-stocks-51631195642?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176976417","content_text":"The White House is set to lay out a plan on Thursday to cut prices for prescription drugs, according to a report out early Thursday from The Wall Street Journal.\nThe plan will allow Medicare to negotiate on drug pricing, and would allow the Department of Health and Human Services to test linking payments for drugs to how the drugs benefit patients, according to the Journal report.\nThe plan would come amid an effort from Congressional Democrats to enact drug-pricing legislation. Both parties have supported efforts to cut prescription- drug prices, though the Trump administration made little progress on the issue.\nThe S&P 500 Pharmaceuticals index is up 14.9% so far this year, trailing behind the broader S&P 500, which has risen 20.2%. The SPDR S&P Biotech\nexchange- traded fund (ticker: XBI), which largely tracks the small and midcap biotech sector, has declined 6% over the same period.\nShares of pharma firms were down in the early morning on Thursday. Pfizer (PFE) shares were down 0.26% in early trading, while Eli Lilly(LLY) shares were down 2.46%, Merck (MRK) shares fell 1.17%, and Johnson & Johnson (JNJ) shares declined 0.7%.\n\nWorries over efforts to limit drug prices have been a long-term overhang on the biotech and pharmaceutical industries. Some analysts have suggested that renewed concerns over drug-price legislation could be one driver behind the recent weakness in biotech stocks.\nAccording to the Journal, the pharmaceutical industry trade group PhRMA is pushing back against the reported White House proposal, and the Democrats’ efforts in Congress, saying on a press call on Wednesday that allowing Medicare to negotiate for drug pricing would mean less money to fund the development of new drugs.\n“The proposals that we’re seeing from Congress will devastate this industry,” Merck chairman Kenneth Frazier said on the press call, according to a report from the news outlet Fierce Pharma, which tracks the industry. “While large companies like Merck will survive, we will do significantly less research.”\nLilly CEO David Ricks also spoke on the call.\n“From the drug industry perspective, the creation of a price negotiation mechanism would be a material negative (as its role may expand over time),” Bernstein analyst Ronny Gal wrote in a note out Tuesday.\nIn addition to the drug-pricing plan, the New York Times reported that President Biden will announce a plan on Thursday to push businesses, schools, and the federal government to adopt strict vaccination policies.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":202,"commentSize":19,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}